Granules Pharmaceuticals, Inc. is a pharmaceuticals company based out of 3701 CONCORDE PKY, Chantilly, Virginia, United States.

At Elutia we are humanizing medicine so patients can thrive without compromise.

Founded in 1960, McCormick Paints is the largest and oldest family-owned independent paint manufacturer on the East Coast. This long history in the region has enabled McCormick to set itself apart from the competition by offering a unique combination of personalized services and regional expertise. McCormick Paints ensures that all customers get the right product for their specific needs and climate, earning the motto, “The Paint the Pros Use.” McCormick Paints prides itself on its agility to manufacture a custom paint solution for customers in the mid-Atlantic region, which national competitors may not be able to accomplish. To support our growth plan, McCormick Paints is committed to recruiting and retaining top talent. We offer unique opportunities. In 2016, McCormick Paints was voted one of the top places to work by the Washington Post. As the company continues to expand its footprint across the mid-Atlantic region, family-owned and operated, McCormick Paints will remain a leader in the manufacturing and delivery of paints and coatings for customers looking to add value, protection and beauty to their property. To learn more, visit our website at www.mccormickpaints.com

ZESTRON - a business division of Dr. O.K. Wack Chemie GmbH, is the global leader in provision of high precision cleaning products, services and comprehensive solutions to the electronics industries. We develop processes for cleaning: - PCB assemblies - Power electronics and packages - Stencils and screens - Machine parts such as condensation traps of relow ovens - Solder frames - Coating pallets With seven technical centers worldwide, cleaning trials can be replicated to the processes conducted on customer sites. Our experienced ZESTRON process engineers are the backbone of this work and support our customers to find the best suitable machine, cleaning agent and process set up. It is ZESTRON’s philosophy to develop cleaning products that are innovative and unprecedented in the industry, thereby ensuring that our customers always remain one step ahead. More than 20% of ZESTRON’s staff is dedicated to our extensive research and development programs, with more than 10% of profit reinvested in this sector. As the innovation leader, we are fully committed to providing the most cost-effective and environmentally sound solutions while meeting all other aspects of cleanliness, reliability and safety requirements.

Neutron Products, Inc. is a company based out of 22301 Mount Ephraim Road, Dickerson, Maryland, United States.

IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

IGC PHARMA is a Pharmaceutical company based in Maryland.

Diligent Heath Solutions is an omni-channel healthcare outsource provider with decades of experience providing Medical Affairs and Commercial services to pharmaceutical, biotech, medical device, and medical technology companies and healthcare organizations. Diligent’s successful delivery of solutions and services is built on a foundation of extensive knowledge and experience. Our expert capabilities include: • Understanding the shifting landscape faced by life science companies. We keep current on the trends that impact life science companies, including patient-centric models, the value of innovative partnerships, and the changing regulatory environment. • Providing second-to-none account management. Our rigorous program management methodologies and laser-focus on clients’ spoken and unspoken needs ensure well-conceived, adeptly-launched and expertly-executed programs and services with a forward focus on strategy and continual improvement. • Providing staff with comprehensive front-line and ongoing training. In addition to in-depth program-specific training, we understand the critical importance of providing our staff with strong foundational knowledge about the industries they serve. Employees consistently rate training as “excellent” in surveys conducted three months into their tenure. • Audit-ready processes. Through the creation of and compliance with robust Standard Operating Procedures (SOPs), we are always in a high state of preparedness for audits conducted by regulatory agencies and our clients’ internal auditors. • Implementing communication-enhancing technologies. Our omni-channel communication capabilities give consumers, patients, caregivers, and health care professionals flexibility in how and when they communicate.

NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology. NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities. For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond.